Quick Answer
Calidi Biotherapeutics, Inc. reported Net Income Loss of -$19.91 million for the year ending 2025.
- Calidi Biotherapeutics, Inc. showed an increase of +10.1% in Net Income Loss from 2024 to 2025.
- This data is from Calidi Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $0.00 | Q2 2021: -$10.0 thousand | Q2 2021: -$83.3 thousand | Q3 2021: -$823.3 thousand | Q1 2022: -$7.74 million | Q2 2022: -$4.58 million | Q3 2022: -$5.36 million | Q1 2023: -$6.46 million | Q2 2023: -$12.50 million | Q3 2023: -$2.02 million | Q1 2024: -$7.23 million | Q2 2024: -$5.77 million | Q3 2024: -$5.05 million | Q1 2025: -$5.06 million | Q2 2025: -$5.72 million | Q3 2025: -$5.15 million.
- Over the full 4 years of available data (2022 to 2025), Calidi Biotherapeutics, Inc.'s Net Income Loss has grown by 21.7%.
- Historical annual values: Fiscal year 2025: -$19.91 million | Fiscal year 2024: -$22.14 million | Fiscal year 2023: -$29.22 million | Fiscal year 2022: -$25.43 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: